Biotech for less than a buck. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than a buck.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (539)	5/5/2000 11:56:00 AM
From: opalapril	Read Replies (1) of 743

Personally, I thought that PR release was nothing more than shameless hype. It sure isn't clear what they were asked, or whether those 'surveyed' understood the implications. Check this line: "One hundred fifty urologists were asked to evaluate separately, on a 0-10 scale, the importance of nine Topiglan(TM) characteristics and findings from Phase I and II trials. Then, for purposes of market research, they were asked to assume that those characteristics and findings, and those of other investigational ED drugs shown at the meeting, would be confirmed in Phase III trials - and to tell which they might recommend to primary care physicians, if all were available for prescription."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next